Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542314 | 1.00 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL19361252 | 0.85 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL12535585 | 0.85 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL12535590 | 0.85 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL13764558 | 0.85 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL172716 | 0.82 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL14864519 | 0.82 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL17541960 | 0.82 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL9918047 | 0.77 | TSHR (0.35) | TSHRALDH1A1 | |
| SCHEMBL1932413 | 0.77 | TSHR (0.35) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| EP-1467990-B1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUE PRECURSORS | SHIRE BIOCHEM INC (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | DCTD, AMPD1, DAD1 | TSHR 3705/4885ALDH1A1 161/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | TSHR 682/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.